A Phase 1 interventional study of LY4336619 and Sofetabart Mipitecan (Sofe-M) in Endometrial Neoplasms, Ovarian Neoplasms and Neoplasms, Germ Cell and Embryonal, sponsored by Eli Lilly and Company. Not yet recruiting at 23 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Endometrial Neoplasms by Eli Lilly and Company — 4 open to participants now, 8 under way, none of them phase 3. Endometrial Neoplasms · Eli Lilly and Company.
Among the 11 studies in Endometrial Neoplasms by Eli Lilly and Company, this one is the 7th largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2026, is one of 6 in phase 1, and was the 11th registered.
1,428 studies on the registry are indexed under Endometrial Neoplasms; 472 are open to participants now.
Browse Endometrial Neoplasms studies →4 of the 11 studies in Endometrial Neoplasms by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Canada, China and 4 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, Australia, France and 4 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, Belgium, France and 6 more countries
Ages 18+
By country, each count listing its studies:
Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 4 · Phase 4 1
First in 1998; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 370 is above the median of 71 across 1,029 interventional studies indexed under Endometrial Neoplasms.
Median enrollment 400 across the 10 interventional studies. Of the 3 that completed or were terminated, 1 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
1 of the studies in Endometrial Neoplasms by Eli Lilly and Company that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04956640Eli Lilly and CompanyStudy of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Endometrial Neoplasms by Eli Lilly and Company, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to evaluate how safe and effective LY4336619 is in adults with advanced cancer. Some participants will receive LY4336619 alone, and some will receive it with another cancer medicine. Participants will be in the study for up to 2 years, depending on how they tolerate and respond to treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Escalating doses of LY4336619 administered intravenously (IV)
Drug: LY4336619
Comparing 2 or more doses (evaluated during dose escalation) of LY4336619 administered IV
Drug: LY4336619
Comparing LY4336619 in combination with Sofe-M administered IV
Drug: LY4336619 · Drug: Sofetabart Mipitecan (Sofe-M)
LY4336619 administered IV
Drug: LY4336619
Administered IV
Administered IV
Number of Participants with Dose-Limiting Toxicities (DLTs)
Time frame: From Cycle 1 Day 1 through Cycle 2 Day 1 (approximately 21 days)
Objective Response Rate (ORR) of LY4336619 in the Dose Expansion Arms
Investigator-assessed ORR per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
Time frame: Up to approximately 2 years
Pharmacokinetics (PK) of LY4336619: Maximum Concentration (Cmax)
Time frame: Up to approximately 2 years
PK of LY4336619: Area under the Concentration-time Curve (AUC)
Time frame: Up to approximately 2 years
PK of Sofe-M in the Combination Cohorts: Cmax
Time frame: Up to approximately 2 years
PK of Sofe-M in the Combination Cohorts: AUC
Time frame: Up to approximately 2 years
ORR of LY4336619
Investigator assessed per RECIST v1.1.
Time frame: Up to approximately 2 years
Duration of Response (DOR) of LY4336619
Per RECIST v1.1.
Time frame: Up to approximately 2 years
Time to Response (TTR) of LY4336619
Per RECIST v1.1.
Time frame: Up to approximately 2 years
Progression-Free Survival (PFS) of LY4336619
Per RECIST v1.1.
Time frame: Up to approximately 2 years
Disease Control Rate (DCR) of LY4336619
Per RECIST v1.1.
Time frame: Up to approximately 2 years
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Mar 2032, 63 months later.
Of 88 industry-sponsored phase 1 interventional studies under Endometrial Neoplasms, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 69. This study's planned 63 months is above that.
Counting every sponsor, half of 131 studies reached it within 61 months; a quarter within 46 and three quarters within 79.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.